Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor versus physician's choice in older patients with relapsed or refractory acute myeloid leukemia
2014-000920-26Phase 2Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of selinexor in acute myeloid leukemia (AML) (2 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Overall survival. Started May 2014; status: completed.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2014-000920-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000920-26.